MGI Tech and Predica Diagnostics Team Up for Precision RNA Sequencing in Oncology
MGI Tech and Predica Diagnostics Team Up for Precision RNA Sequencing in Oncology
NIJMEGEN, Netherlands, July 11, 2024 /PRNewswire/ -- MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with Predica Diagnostics, a leading innovator in oncology diagnostics, to develop Predica's targeted RNA sequencing tests on the cost-effective MGI Next-generation sequencing platforms.
2024年7月11日,荷兰尼姆荷亨——生命科学创新核心工具和技术制造商MGI(MGI Tech Co.,Ltd.及其子公司合称MGI)宣布与肿瘤诊断创新领军者Predica Diagnostics合作,通过MGI下一代测序平台研发Predica的靶向RNA测序检测。
The collaboration seeks to revolutionize molecular diagnostics by enabling early cancer detection and facilitating personalized targeted treatment strategies. By combining Predica Diagnostics' advanced sequencing assays with MGI's state-of-the-art Next-generation sequencing platforms, the initiative promises a rapid, accurate, and affordable solution for healthcare providers.
这次合作旨在通过将Predica Diagnostics的先进的测序检测与MGI的最先进的下一代测序平台相结合,革命性地实现早期癌症检测和个性化靶向治疗,承诺为医疗保健提供快捷、准确和经济实惠的解决方案。
Empowering Precision Medicine
赋能精准医学
Predica Diagnostics, renowned for its expertise in cervical cancer screening through its proprietary ciRNAseq-based test, CervicaDx, brings unparalleled precision in identifying high-risk HPV oncogenes and other (pre)malignancy biomarkers. By integrating this advanced diagnostic capability with MGI's robust and affordable DNBSEQ technology, the partnership aims to significantly enhance the accuracy and accessibility of diagnostic tests.
以其专有的ciRNAseq测试——CervicaDx在宫颈癌筛查方面的专长而闻名的Predica Diagnostics,提供了识别高风险HPV癌基因和其他(前)恶性生物标志物的无与伦比的精准度。将这种先进的诊断能力与MGI的坚固而经济实惠的DNBSEQ技术相结合,该合作伙伴关系旨在显著提高诊断测试的准确性和可访问性。
Enhancing Affordability and Accessibility
提高可负担性和可访问性
A core value of this partnership is making high-quality diagnostic and predictive testing more affordable and accessible. MGI Tech's DNBSEQ platforms, recognized for their cost-efficiency and scalability, will enable healthcare institutions to offer advanced genomic and transcriptomic testing at a lower cost. Compared to existing NGS-based technologies, MGI's platform offers cost-effective and faster results. Within the collaboration, MGI's NGS platform will be deployed for conducting the final analysis of Predica's disruptive, ciRNAseq-based targeted RNA sequencing tests. This combination will help researchers and healthcare professionals to better predict patient prognosis and guide treatment with precision medicines.
该合作伙伴关系的核心价值观是使高质量的诊断和预测测试更加经济实惠和易于获得。MGI Tech的DNBSEQ平台以其成本效益和可扩展性而闻名,将使医疗机构能够以更低的成本进行先进的基因组和转录组测试。与现有的NGS技术相比,MGI的平台提供了更经济实惠和更快速的结果。在此合作中,MGI的NGS平台将被部署进行Predica颠覆性的ciRNAseq中的靶向RNA测序测试的最终分析。此组合将有助于研究人员和医疗保健专业人员更好地预测患者预后,并指导精准医学的治疗。
A Shared Vision for the Future
共同拥抱未来愿景
"Predica welcomes MGI as a partner with expertise that is highly synergistic with that of Predica", says Dr. William Leenders, CSO of Predica Diagnostics. "Where our expertise lies in providing smart molecular diagnostic solutions for unmet medical needs, we see the combination with MGIs sequencing platforms as a perfect match for customers to get clinically important information on gene expression without the need for any on-site bio-informatic expertise."
Predica Diagnostics的首席科学家William Leenders博士表示:“Predica欢迎MGI作为非常具有协同作用的合作伙伴,两家公司的专业知识融合是完美的匹配,可以向客户提供基因表达的临床重要信息而不需要任何现场生物信息专业知识。”
Dr. Yong Hou, General Manager of MGI Europe and Africa, adds, "This partnership embodies our commitment to advancing healthcare through innovative genomic solutions. By combining our affordable and high-performance sequencing technology with Predica's expert diagnostic kits, we are poised to make a significant impact in the field of personalized medicine."
MGI Tech欧洲和非洲区总经理侯勇博士补充道:“这项合作体现了我们通过创新的基因组解决方案来推进医疗保健的承诺。通过将我们经济实惠的高性能测序技术与Predica的专业诊断工具相结合,我们将有望在个性化医学领域产生重大影响。”
MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and has established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , LinkedIn, X, and YouTube.
MGI Tech Co.,Ltd.(及其子公司合称MGI)致力于构建推动生命科学创新的核心工具和技术。我们专注于生命科学和生物技术领域中仪器、试剂和相关产品的研发、制造和销售。我们为精准医学、农业、医疗保健及其他各种产业提供实时、多组学和全谱数字设备和系统。成立于2016年的MGI已成长为生命科学领域的领先企业,服务于全球六大洲的客户,并在全球范围内建立了研究、制造、培训和售后服务设施。无论是Gb到Tb的吞吐量,MGI都是为数不多具备独立开发和批量生产临床级基因测序仪的公司之一。凭借其无与伦比的专业知识、前沿产品和全球影响力的承诺,MGI不断塑造未来的生命科学轨迹。要了解更多信息,请访问、LinkedIn、X或YouTube。
Predica Diagnostics B.V is a spinoff from the Radboud UMC, active in the field of diagnostics, prognostics and prediction of treatment response in oncology. Predica Diagnostics aims to bring its ciRNAseq technology to patients in 1 to 2 years with a first focus on the CervicaDx test for improved cervical cancer screening. The test allows non-invasive detection of cervical abnormalities with unprecedented specificity in women with a positive HPV test. Other tests in development concern tests to detect host-microbiome interactions and tests to detect activity of biological pathways and mutations that are amenable for targeted treatment with precision medicines, enabling the development of personalized treatment plans for cancer patients.
Predica Diagnostics b.V是Radboud UMC的一个分支,活跃于肿瘤学的诊断、预后和预测治疗反应领域。Predica Diagnostics旨在通过1至2年内将其ciRNAseq技术应用于患者身上,首先将焦点放在CervicaDx测试上,以改进宫颈癌筛查。该测试可允许在女性HPV阳性的情况下无创检测宫颈异常,具有前所未有的特异性。其他开发中的检测涉及检测宿主微生物组间互动和检测易于靶向治疗的生物路径和突变的活性,从而实现了癌症患者个性化治疗计划的制定。
Logo -
Logo -